Additionally, the TrLp-induced p53 activation can cause suppression of CD133(+) and SOX2(+) GBM stem cells (in GL261 culture), which are known to cause tumor recurrence even after the available therapies (Figure 4) [9,24,44,45]. Here, SOX2 is linked to neoplasm.